On July 22, Science Corporation — the neurotech company led by Max Hodak — received European regulatory approval for PRIMA, its retinal-implant system, clearing the path toward a commercial rollout. PRIMA pairs a tiny photovoltaic chip implanted beneath the retina with a set of camera glasses: the glasses capture the scene and project it, in infrared, onto the chip, whose micro-photodiodes convert that light into electrical signals that stimulate the remaining retinal neurons. For people who’ve lost central vision to geographic atrophy (advanced dry age-related macular degeneration), it has enabled reading letters and words again — a form of engineered sight.
How the “chip plus glasses” system works
What makes PRIMA notable for this site’s neural-interface beat is its elegant division of labor. The implant is deliberately simple and passive — a wireless, solar-cell-like array with no batteries or wires running out of the eye — because it draws its power and its image directly from the infrared light the glasses beam in. The glasses do the heavy lifting: a camera captures the world, an onboard processor interprets it, and the image is projected onto the chip, which the brain learns to read as vision. That architecture (smart wearable + minimal, durable implant) is a recurring theme in the most promising neural interfaces, and it’s why “implant plus glasses” is the phrase that matters here.
Why regulatory approval is the real milestone
Sight-restoration devices have a long, heartbreaking history of promising trials followed by companies folding and leaving implanted patients stranded when support ended. That context is exactly why regulatory approval and a path to commercial rollout — not just another study — is the meaningful news. Clearing European regulators signals a device judged safe and effective enough to reach patients at scale, with the commercial infrastructure to support them over time. It moves PRIMA from “remarkable research result” toward “product a clinic can actually offer,” which is the leap most neurotech never makes.
Where it sits in the bigger picture
PRIMA belongs to the same broad story this site has followed through BrainGate, Synchron, and other neural interfaces: technology restoring capabilities that disease or injury took away, and in doing so redrawing the boundary between the biological and the engineered. It’s vision-restoration, not a creative tool — and the honest caveats are real: it addresses specific forms of vision loss, the restored sight is functional rather than natural, and learning to use it takes training. But engineered vision reaching regulatory approval is a genuine landmark, and the “camera glasses driving a passive implant” design is the kind of human-machine architecture worth understanding as these interfaces mature.